Resilience

Founded in 2021 and based in Paris, France, Resilience SAS operates as a software-based solution for cancer treatment providers and patients. Founded in the United States, the company has expanded its global footprint, establishing a presence in Europe, Asia, and Africa, with a network of research and care facilities across these regions. At the core of Resilience Care's offerings are its healthcare products and services, which span multiple domains, including mental health, chronic disease management, and rehabilitation. The company's multidisciplinary approach combines medical technologies, evidence-based therapies, and personalized care plans for patients. Resilience Care's product portfolio includes a suite of digital health tools, such as mobile applications and telehealth platforms, that enable remote monitoring, personalized treatment plans, and seamless communication between patients and healthcare providers. Additionally, the company operates a network of specialized care facilities, where patients can access a range of services, including counseling, physical therapy, and support groups. Resilience Care's revenue streams are primarily derived from the provision of its healthcare services and the sale of its digital health products. The company also generates income through research grants and partnerships with academic institutions, government agencies, and other healthcare organizations.

1. Series B

   May 21, 2024

   Amount

   $25M

   Investors

   Locked

2. Series A

   Mar 2, 2022

   Amount

   $44M

   Investors

   Locked